Dolutegravir in Patients with Raltegravir-Resistant HIV

VIKING (Cohorts I & II)
## Study Design: VIKING

### Background
Single-arm, phase 2b trial evaluating efficacy of once daily or twice daily dolutegravir in patients with integrase resistance.

### Inclusion Criteria (n=51)
- Age ≥18 years old
- HIV RNA >1,000 copies/mL
- Documented resistance ≥3 ARV classes, including integrase inhibitors

### Treatment Arms
- Cohort I*: dolutegravir 50 mg once daily
- Cohort II*: dolutegravir 50 mg twice daily

*Failing regimen continued during day 1-10, then replaced with OBR through week 24
Dolutegravir in Patients with Raltegravir Resistance
VIKING Study (Cohorts I & II): Results

Week 24 Virologic Response

**Conclusion**: “Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to raltegravir.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*